April 10, 2015
The tenth meeting of National Cancer Institute Directors will take place in Lyon between 8th and 10th July, 2015. The previous meeting attracted over 100 participants from 50 countries at varying levels of income and resource. The 2015 meeting has already attracted a great deal of interest and several projects initiated at our last meeting have come to fruition.
As requested by participants, the focus on cancer care will continue to increase with the sharing of experience in a wide variety of resource settings underlined. The meeting in 2015 will see discussion of “World Bladder Cancer Report 2015” which will be launched at this meeting. Once again, this report will highlight the disparities which exist in the diagnosis, treatment and outcome of this important disease. Two other Reports will be discussed at this meeting: “State of Oncology in Africa 2015” and “State of Oncology in the Indian Sub-Continent 2016”. These two latter reports will refer to the current state of oncology in nearly one half of the world’s population.
To mark the fortieth anniversary of his discovery of the cure of testicular cancer, Dr Larry Einhorn will give a keynote address at the meeting in 2015. Dr Einhorn has been a major figure in Oncology and his discovery of the role of cis-platin in the treatment of disseminated testicular cancer remains one of the key contributions to cancer treatment. Dr Tadao Kakizoe, a pioneering urological surgeon, will also give a keynote lecture on his work on innovative approaches to Bladder Cancer surgery.
There will be sessions, some of which will be approximately one half day, devoted to the themes of (1) barriers to re-imbursement of new therapies; (2) liver cancer diagnosis, treatment and prevention; (3) focus of cancer in North Africa, Middle East and Central Asia Republics; (4) the Next11 countries (Bangladesh, Egypt, Indonesia, Iran, Korea, Mexico, Nigeria, Pakistan, Philippines, Turkey and Vietnam); and (5) prevention of incidence and mortality from melanoma. The important issue of ‘Access’ will be a key thread running through all these sessions.
On behalf of iPRI and the World Prevention Alliance, I would like to thank you for your participation in this meeting where your expertise will be invaluable in contributing to worldwide cancer prevention.